Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1a/1b dose escalation and expansion study to evaluate the effect of HDP-101 for the treatment of Multiple Myeloma

Trial Profile

A phase 1a/1b dose escalation and expansion study to evaluate the effect of HDP-101 for the treatment of Multiple Myeloma

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HDP 101 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 10 Oct 2019 According to an Heidelberg Pharma AG media release, the company is expected to file for a clinical trial application in the second half of 2020.
    • 21 May 2019 According to an Heidelberg Pharma AG media release, the company aim to treat the first multiple myeloma patient with their first ATAC candidate (HDP-101) in 2020.
    • 21 Mar 2019 According to a Heidelberg Pharma media release, pplications for the Phase Ia (dose escalation) and Phase Ib (dose expansion) will be submitted simultaneously in the USA and Germany.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top